Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP11 | Q9NR21 | 9/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 8/20 | 0.58 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.54 |
| ▸ | GRM5 | P41594 | 3/20 | 0.54 |
| ▸ | PRKACA | P17612 | 1/20 | 0.53 |
| ▸ | PRKACG | P22612 | 1/20 | 0.53 |
| ▸ | PRKACB | P22694 | 1/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TDP2 | O95551 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30337030 | 1.00 | PARP11 (0.58) | PARP11PARP10SRD5A1SRD5A2GRM5 | |
| SCHEMBL29631237 | 0.87 | PARP10 (0.58) | PARP11PARP10SRD5A1SRD5A2PDPK1 | |
| SCHEMBL20894239 | 0.87 | PARP10 (0.58) | PARP11PARP10SRD5A1SRD5A2PDPK1 | |
| SCHEMBL8885387 | 0.85 | PARP11 (0.49) | PARP11PARP10SRD5A1SRD5A2GRM5 | |
| SCHEMBL30421037 | 0.85 | PARP10 (0.57) | PARP11PARP10GRM5PRKACAPRKACG | |
| SCHEMBL1727165 | 0.85 | PARP11 (0.72) | PARP11PARP10GRM5PRKACAPRKACG | |
| SCHEMBL14332678 | 0.83 | SMYD3 (0.58) | SRD5A1SRD5A2GRM5KDM4EMAPT | |
| SCHEMBL12810163 | 0.83 | PARP10 (0.54) | PARP11PARP10GRM5PRKACAPRKACG | |
| SCHEMBL12683051 | 0.81 | PRKACA (0.58) | PARP11PARP10GRM5PRKACAPRKACG | |
| SCHEMBL30336933 | 0.81 | PRKACA (0.58) | PARP11PARP10GRM5PRKACAPRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3706747-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| CN-115916176-A | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | 加利福尼亚大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| US-20200354377-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-11-12 | — | — | US | disclosed |
| EP-3706747-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190270733-A1 | Quinoline and Isoquinoline Based HDAC Inhibitors and Methods of Use Thereof | GOLUB CAPITAL LLC, AS COLLATERAL AGENT | 2019-09-05 | — | — | US | disclosed |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | Venenum Biodesign, LLC (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2017214359-A1 | NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS | VENENUM BIODESIGN LLC (US) | 2017-12-14 | — | — | WO | disclosed |
| EP-2298747-B1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2016-12-28 | — | — | EP | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-2298747-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270733-A1 | Quinoline and Isoquinoline Based HDAC Inhibitors and Methods of Use Thereof | HDAC5, HDAC1, HDAC2 | PARP11 284/4885PARP10 305/4885SRD5A1 3193/4885 |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | GABRA5, GABRA1, GABRA4 | PARP11 4072/4885PARP10 3680/4885SRD5A1 766/4885 |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | PARP11 1644/4885PARP10 2809/4885SRD5A1 14/4885 |
| US-20200354377-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | PARP11 105/4885PARP10 142/4885SRD5A1 1877/4885 |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | GABRA5, GABRA1, GABBR2 | PARP11 3934/4885PARP10 3565/4885SRD5A1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.